Skip to main content
Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions

Pharmacology Watch: FDA Recommends Approval of Muraglitazar, But May Need To Reconsider